EconPapers    
Economics at your fingertips  
 

Intestinal permeability of N-acetylcysteine is driven by gut microbiota-dependent cysteine palmitoylation

Yu-Hang Zhang (), Chen-Shu Dai, Ya-Jie Wang, Wen-Yu Wang, Tian-Tian Qi, Man-Cheng Xia, Gan Zhou () and Yi-Min Cui ()
Additional contact information
Yu-Hang Zhang: Peking University First Hospital
Chen-Shu Dai: Peking University First Hospital
Ya-Jie Wang: Peking University First Hospital
Wen-Yu Wang: Capital Medical University
Tian-Tian Qi: Peking University First Hospital
Man-Cheng Xia: Peking University First Hospital
Gan Zhou: Xiangya Hospital of Central South University
Yi-Min Cui: Peking University First Hospital

Nature Communications, 2025, vol. 16, issue 1, 1-15

Abstract: Abstract Trillions of intestinal microbiota are essential to the permeability of orally administered drugs. However, identifying microbial-drug interactions remains challenging due to the highly variable composition of intestinal flora among individuals. Using single-pass intestinal perfusion (SPIP) platform, we establish the microbiota-based permeability screening framework involving germ-free (GF) and specific-pathogen-free (SPF) rats to compare in-situ Peff-values and metabolomic profiles of 32 orally administered drugs with disputable classifications of permeability, prior to the verifications of bioorthogonal chemistry and LC-MS/MS. In contrast with SPF controls, N-Acetylcysteine (NAC) exhibits significantly increased permeability in GF rats, which is inversely related to reduced cysteine-3-ketosphinganine by Bacteroides. To further validate these microbiome features, we integrate clinical descriptors from a prospective cohort of 319 participants to optimize a 15-feature eXtreme Gradient Boosting (XGB) model, which reveal that cysteine palmitoylation by intestinal microbiota has significantly affected NAC permeability. By comparison of net reclassification improvement (NRI) index, this machine learning (ML) model of clinical prediction model encompassing intestinal microbial features outperforms other three commercial models in predicting NAC permeability. Here we have developed an intestinal microbiota-based strategy to evaluate uncharacterized NAC permeability, thus accounting for its discordant biopharmaceutics classification.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-59916-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59916-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-59916-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-05-20
Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59916-7